Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03467867 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv14
  2. Primary completion date: Oct 2025 to Dec 2026 Completion date: Jan 2026 to Dec 2026v13 Show 1 more changeShow less
    • Completion date: Jan 2026 to Dec 2026
  3. Primary completion date: Jun 2025 to Oct 2025v12
  4. Primary completion date: Nov 2024 to Jun 2025 Completion date: Nov 2024 to Jan 2026v11 Show 1 more changeShow less
    • Completion date: Nov 2024 to Jan 2026
  5. Primary and study completion dates: Oct 2024 to Nov 2024v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Primary and study completion dates: Oct 15, 2023 to Oct 2024v8
  3. Re-verified, no change to tracked fieldsv7
  4. Trial status: Recruiting to Active, Not Recruiting Site details revised at 2 of 2 sitesv6 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  5. Re-verified, no change to tracked fieldsv5
  6. Study sites: 1 to 2v4
  7. Re-verified, no change to tracked fieldsv3
  8. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 15, 2018 to Apr 26, 2018v2 Show 1 more changeShow less
    • Start date changed from estimate of Apr 15, 2018 to Apr 26, 2018
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Trial Details
NCT Number NCT03467867
Lead Sponsor Georgetown University
Collaborators: Hackensack Meridian Health
Conditions Chronic Lymphocytic Leukemia
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov